Recurrent Melanoma Completed Phase 2 Trials for Aflibercept (DB08885)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01258855Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryTreatment
NCT00450255VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryTreatment